FDA
-
-
-
-
-
-
-
New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
-
-
-
-
-
-
-
Definium begins second phase 3 study of DT120 for depression
-
-
-
-
-
-
-
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
-
-
-
-
-
329,909 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

